Skip to main content

QIAGEN launches novel tuberculosis test for high-burden regions

News


Abstract

QIAGEN N.V. has announced the launch and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing access to easy and reliable TB testing, especially in high burden countries, low-resource regions. QIAreach® QuantiFERON®-TB is a portable device that enables the ultrasensitive digital detection of TB infection with an end-to-end workflow that is simple and cost efficient, and increases access to reliable Interferon Gamma Release Assay (IGRA) testing.
Key Data

  • Publication Date
    20 October 2021
  • Primary Author
    BioSpectrum
  • Source
    BioSpectrum
  • Language
    English
Click below to visit original source: